Clarus Therapeutics (CRXT) Misses Q1 EPS by 21c

Clarus Therapeutics (NASDAQ: CRXT) reported Q1 EPS of ($0.61), $0.21 worse than the analyst estimate of ($0.40). Revenue for the quarter came in at $4 million versus the consensus estimate of $5.5 million.

For earnings history and earnings-related data on Clarus Therapeutics (CRXT) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• KULR Technology Group (KULR) Misses Q2 EPS by 39c
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c